This year Amiprox visitied the DGP for the first time. The main purpose was to learn about COPD, meet the KOL’s working in the area and advance discussions with our current contacts.
The DGP was very useful with some of the best experts in the area speaking. The key area of development of the last few years was considered to be the development of biologics, especially for Type 2 inflammation. Most of the new biologics, being very expensive, are used in this area. In contrast the area of biomarkers has made little progress in the last few years. The key markers of Type 2 inflammation are considered to be eosinophils >300, which may be rather variable, and FeNO concentrations. Though this was considered to be good enough but any new developments would be most welcome.
Another interesting development was the importance of complications in COPD, especially cardiovascular diseases.
A new radiological biomarker was mucus plugs, which could be determined using AI, but are still in an early stage.
Other focus areas were asthma, lung cancer and interstitial lung disease. The meeting is very well organized with approx. 4500 participants, making it of a good size.
